2 days Ago By ABMN Staff
Equities research analysts at StockNews.com assumed coverage on shares of CytomX Therapeutics ( NASDAQ:CTMX – Get Free Report ) in a note issued to investors on Tuesday. The firm set a “hold” rating on the biotechnology company’s stock.
Other equities analysts also recently issued research reports about the stock. HC Wainwright reiterated a “neutral” rating on shares of CytomX Therapeutics in a research note on Friday, March 7th. Piper Sandler started coverage on CytomX Therapeutics in a research report on Monday.
They set an “overweight” rating and a $2.50 target price on the stock. Finally, Wedbush reaffirmed an “outperform” rating and issued a $5.
00 price target on shares of CytomX Therapeutics in a report on Friday, March 7th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $4.
77. Read Our Latest Report on CTMX CytomX Therapeutics Trading Down 0.3 % CytomX Therapeutics ( NASDAQ:CTMX – Get Free Report ) last announced its quarterly earnings data on Thursday, March 6th.
The biotechnology company reported $0.22 EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.
45. The business had revenue of $38.09 million during the quarter, compared to the consensus estimate of $13.
53 million. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.
96%. On average, equities analysts forecast that CytomX Therapeutics will post -0.05 EPS for the current fiscal year.
Institutional Inflows and Outflows Hedge funds have recently added to or reduced their stakes in the company. FMR LLC grew its position in shares of CytomX Therapeutics by 17.3% during the third quarter.
FMR LLC now owns 284,307 shares of the biotechnology company’s stock worth $335,000 after acquiring an additional 41,949 shares during the last quarter. Geode Capital Management LLC grew its position in CytomX Therapeutics by 4.4% during the 3rd quarter.
Geode Capital Management LLC now owns 803,531 shares of the biotechnology company’s stock worth $948,000 after purchasing an additional 34,032 shares during the last quarter. Virtu Financial LLC acquired a new position in CytomX Therapeutics in the third quarter valued at $104,000. Traphagen Investment Advisors LLC purchased a new stake in shares of CytomX Therapeutics in the fourth quarter valued at about $31,000.
Finally, Miller Financial Services LLC acquired a new stake in shares of CytomX Therapeutics during the fourth quarter worth about $26,000. Hedge funds and other institutional investors own 67.77% of the company’s stock.
About CytomX Therapeutics ( Get Free Report ) CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. Read More Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
_0.jpg?itok=yAIF6nFK)
